- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
53
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
53 companies
Madrigal Pharmaceuticals
Market Cap: US$13.6b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$598.91
7D
-0.7%
1Y
92.2%
Arcutis Biotherapeutics
Market Cap: US$3.5b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$28.97
7D
-3.1%
1Y
104.0%
Caris Life Sciences
Market Cap: US$8.0b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$28.24
7D
-0.8%
1Y
n/a
Marker Therapeutics
Market Cap: US$23.9m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.44
7D
1.1%
1Y
-57.0%
Mereo BioPharma Group
Market Cap: US$367.6m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$2.31
7D
0.9%
1Y
-34.4%
Legend Biotech
Market Cap: US$4.2b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$22.53
7D
-0.7%
1Y
-31.2%
Lineage Cell Therapeutics
Market Cap: US$399.8m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.65
7D
-4.6%
1Y
232.7%
ARS Pharmaceuticals
Market Cap: US$1.1b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$11.38
7D
0.2%
1Y
7.2%
Soleno Therapeutics
Market Cap: US$2.6b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$47.65
7D
-3.5%
1Y
5.2%
Achieve Life Sciences
Market Cap: US$238.8m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.49
7D
0.6%
1Y
24.2%
Aldeyra Therapeutics
Market Cap: US$319.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.31
7D
-4.2%
1Y
5.8%
RenovoRx
Market Cap: US$31.3m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.85
7D
-5.0%
1Y
-38.5%
Pelthos Therapeutics
Market Cap: US$79.4m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$25.71
7D
-3.9%
1Y
306.2%
Capricor Therapeutics
Market Cap: US$1.5b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$29.69
7D
0.6%
1Y
115.8%
Citius Oncology
Market Cap: US$95.8m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.13
7D
-9.6%
1Y
0.9%
Viridian Therapeutics
Market Cap: US$3.0b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$31.88
7D
-1.8%
1Y
63.2%
Syndax Pharmaceuticals
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.30
7D
-0.8%
1Y
70.1%
Precigen
Market Cap: US$1.5b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.16
7D
-5.0%
1Y
345.8%
AC Immune
Market Cap: US$309.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.13
7D
-1.6%
1Y
17.2%
Longeveron
Market Cap: US$11.4m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.53
7D
-1.5%
1Y
-69.9%
Altimmune
Market Cap: US$402.8m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$3.86
7D
-6.8%
1Y
-47.3%
Insmed
Market Cap: US$37.9b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$177.88
7D
1.2%
1Y
158.3%
Vera Therapeutics
Market Cap: US$3.8b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$53.58
7D
-0.4%
1Y
27.4%
Praxis Precision Medicines
Market Cap: US$6.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$268.95
7D
-4.1%
1Y
252.7%
Rhythm Pharmaceuticals
Market Cap: US$7.3b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$110.00
7D
-2.6%
1Y
95.2%
Unicycive Therapeutics
Market Cap: US$130.5m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.07
7D
3.8%
1Y
-25.2%
SELLAS Life Sciences Group
Market Cap: US$408.8m
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$2.87
7D
8.7%
1Y
189.0%
Roivant Sciences
Market Cap: US$15.5b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$22.23
7D
-2.0%
1Y
94.5%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.74
7D
-1.7%
1Y
9.3%
BioRestorative Therapies
Market Cap: US$9.9m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.12
7D
-3.4%
1Y
-22.2%
Creative Medical Technology Holdings
Market Cap: US$7.8m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$2.10
7D
-0.9%
1Y
-10.3%
Prelude Therapeutics
Market Cap: US$201.9m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$2.45
7D
8.4%
1Y
102.5%
Amicus Therapeutics
Market Cap: US$4.4b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.25
7D
0.3%
1Y
51.4%
Day One Biopharmaceuticals
Market Cap: US$970.3m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$9.45
7D
-1.3%
1Y
-24.9%
Savara
Market Cap: US$1.6b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$6.45
7D
-0.3%
1Y
109.4%
Cogent Biosciences
Market Cap: US$5.9b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$38.88
7D
-1.2%
1Y
404.3%